Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
teclistamab + autologous lymphocyte infusion
- Development stage
- Unknown
- Lead developer
- Janssen Biotech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cell Therapies
- Administration
- Subcutaneous, Intravenous
01
Overview
Teclistamab + autologous lymphocyte infusion (ALI) is an investigational combination therapy being evaluated for the treatment of relapsed or refractory multiple myeloma (RRMM). Teclistamab is a humanized bispecific T-cell engager (BiTE) that targets B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T lymphocytes, thereby facilitating T-cell-mediated cytotoxicity. The addition of autologous lymphocyte infusions (ALI) aims to replenish or enhance the T-cell pool to improve the duration of response and efficacy of teclistamab, particularly in patients who have achieved at least a partial response after initial teclistamab monotherapy. This specific combination is being studied in the Phase II TALIM trial (NCT06933277) sponsored by the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA).
- Other names
- Teclistamab + ALITALIM regimen
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on teclistamab + autologous lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on teclistamab + autologous lymphocyte infusion.